For instance, patients with BRAF mutant tumours, liver metastases, symptomatic brain metastases and elevated lactate dehydrogenase (LDH) levels showed improved survival outcomes with combination therapies, although the most effective treatment strategies for other subgroups remain a pressing and unresolved issue [6,7]. The gene discussed is BRAF; the disease is neoplasm.